BCL2 and acute lymphoblastic leukemia: Accordingly, Khaw and colleagues showed venetoclax to be effective against only a minority of B-ALL xenografts in vivo, whereas combined BCL-2/BCL-xL inhibition resulted in synergistic killing in most models [47].